Culture

Piper Jaffray Companies Reiterates "Overweight" Rating for Alnylam Pharmaceuticals, Inc. (ALNY)

Piper Jaffray Companies Reiterates

TIAA CREF Investment Management LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. This represents a change from most recent open price of 5.88%. Perceptive Advisors has an ownership of 1,103,475 stocks of the biopharmaceutical firms shares valued $56,553,000 following purchasing an extra 985,000 shares through out the quarter. As of quarter end Janus Capital Management LLC had bought a total of 136,469 shares growing its holdings by 26.6%.

A number of other brokerages also recently issued reports on ALNY.

Artal Gp Sa invested 0.42% of its portfolio in Alnylam Pharmaceuticals, Inc. Lastly, Russell Investments Group upgraded its stake in stocks of Alnylam Pharmaceuticals by 341.1% in the 1st period.

Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock. Neuberger Berman Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $205,000. Finally, Baillie Gifford & Co. raised its stake in shares of Alnylam Pharmaceuticals by 2.9% in the second quarter. Institutional investors and hedge funds own 89.71% of the company's stock. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/09/10/barclays-plc-reaffirms-overweight-rating-for-alnylam-pharmaceuticals-inc-alny.html. (NASDAQ:ALNY) traded up 1.13% during mid-day trading on Tuesday, hitting $43.99. The company was maintained on Wednesday, April 12 by RBC Capital Markets. The stock is trading $81.46 its 50-day moving average by 7.77%.

14-day Williams %R for Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, November 2nd. Analysts are forecasting earnings of $-1.18 on a per share basis this quarter. The company's end of quarter revenue went up 82.9% compared with the same period in the prior year. Last session Alnylam Pharmaceuticals, Inc. Analysts expect next quarter's EPS will be $-1.35 with next year's EPS projected to be $-5.33.

Now we will discuss the financial strength of Alnylam Pharmaceuticals, Inc. OraSure Technologies had 15 analyst reports since August 6, 2015 according to SRatingsIntel. Chardan Capital reissued a "buy" rating and set a $124.00 price target (down from $131.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. Needham & Company LLC downgraded Alnylam Pharmaceuticals to a "buy" rating and lowered their price objective for the company from $152.00 to $137.00 in a research report on Thursday, October 6th. Vetr downgraded Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating and set a $71.50 price objective for the company.in a research note on Monday, May 15th. Jefferies maintained it with "Buy" rating and $102.0 target in Thursday, August 24 report. August 10 investment analysts at Morgan Stanley left the stock rating at "Equal-Weight" but raised the price target to $50.00 from $46.00. With 677,700 avg volume, 13 days are for Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY)'s short sellers to cover ALNY's short positions. Price Target plays a critical role when it comes to the analysis of a Stock.

Peter Algert decreased its stake in Orasure Technologies Inc (OSUR) by 88.88% based on its latest 2016Q4 regulatory filing with the SEC. The stock plummeted -5.79 percent over the past month and rose 96.82 percent year-to-date. 17,200 shares valued at $1.86 million were sold by VAN SANT R WILLIAM on Monday, May 1. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company's stock worth $413,811,000 after acquiring an additional 441,957 shares in the last quarter. The disclosure for this sale can be found here. The Return on Investment (ROI) ratio of Alnylam Pharmaceuticals, Inc. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates created to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. (NASDAQ:ALNY). D E Shaw And Com reported 215,426 shares or 0.01% of all its holdings.



Like this

loading...
loading...

Latest


12 September 2017
Scotiabank Cuts Continental Resources, Inc. (CLR) Price Target to $13.50
Among 33 analysts covering Continental Resources Inc. (NYSE:CLR) has risen 4.05% since September 11, 2016 and is uptrending. State Of Tennessee Treasury Department reported 240,000 shares. (NYSE:CLR), 20 have Buy rating, 0 Sell and 13 Hold.

11 September 2017
Manchester United 'reserve No.7 shirt for Antoine Griezmann'
Atletico Madrid' 26-years-old star still in the MU wish list. He is quite a while being a long-time target for them. Let us know your thoughts in the comments.

11 September 2017
Injustice 2 PC listed on Amazon France
So, it's important to take all of the information regarding Injustice 2's possible PC version with a grain of salt. No further details have been provided, and only the Deluxe Edition of the game has been listed for a PC release.

11 September 2017
Protests in South Korea as nations wrestle with North missile threat
Putin said Pyongyang would not end its nuclear and missile programmes because it viewed them as its only means of self-defence. Residents believe the THAAD systems will turn their town into a primary target in the case of an attack from North Korea.

11 September 2017
Awkward! Tony Romo conducts interview with Phil Simms, the analyst he replaced
Several times during the game, Romo correctly predicted which plays teams were going to run before they happened. Romo provided more than just color commentary during the Oakland Raiders-Tennessee Titans game.

11 September 2017
Kinder Morgan Sees Unusually High Options Volume (KMI)
Note, this compares with a consensus analyst forecast of 0.15 in earnings per share for its next fiscal quarterly report. Pring Turner Capital Group Inc decreased Kinder Morgan Inc Del Com (KMI) stake by 15.04% reported in 2016Q4 SEC filing.

11 September 2017
Patient kills foreign Red Cross staffer in Afghanistan
The gunmen believed to be loyalists of the ISIS terrorist group also kidnapped a number of the ICRC staff member after the attack. Police told the BBC the men had disabilities, and had hidden guns in their plastic prosthetic legs.

11 September 2017
Leslie Jones' reaction during NYFW fashion show is hilarious
As model Coco Rocha made her way down the runway, she was hyped by Leslie who screamed her support at the model. The supermodel couldn't help but smile, and began to pose in front of the star.

11 September 2017
IShares Edge MSCI USA Momentum Factor (MTUM) Rises 1.1% for Sep 11
The fund owned 39,660 shares of the exchange traded fund's stock after purchasing an additional 3,161 shares during the period. It is quite reasonable to be optimistic about the investment environment heading into the second half of the year.

11 September 2017
Bernstein Reiterates Outperform Rating for Schlumberger NV (SLB)
Tower Limited Liability Com (Trc) holds 0% of its portfolio in Nexstar Media Group Inc (NASDAQ:NXST) for 192 shares. (NYSE:HES). Since January 1, 0001, it had 3 buys, and 0 selling transactions for $344,067 activity. $250,203 worth of Schlumberger Limited.